Indications for Fresh Frozen Plasma (FFP)
Fresh frozen plasma should be transfused primarily for major hemorrhage with coagulopathy, acute DIC with bleeding, and urgent warfarin reversal when prothrombin complex concentrate is unavailable 1.
Primary Indications for FFP
Based on the most recent 2025 Association of Anaesthetists guidelines, FFP is indicated for 1:
- Major hemorrhage: Administered in balanced ratio with RBCs (typically 1:1 or 1:1.5) until coagulation test results are available
- Disseminated intravascular coagulation (DIC) with evidence of bleeding or high bleeding risk (e.g., planned surgery/invasive procedure)
- Urgent warfarin reversal in the presence of active bleeding when prothrombin complex concentrate is not available
- Replacement fluid for apheresis in microangiopathies (thrombotic thrombocytopenic purpura, hemolytic uremic syndrome)
- Hereditary angioedema (FFP contains C1-esterase inhibitor)
The 2016 AAGBI guidelines provide additional specific laboratory thresholds 2:
- Actively bleeding patients with INR >1.5 (or point-of-care equivalent)
- Coagulation factor deficiency in massive transfusion (>1 blood volume or ~70 ml/kg) when PT/INR and aPTT cannot be obtained timely
- Specific coagulation factor deficiencies when specific concentrates are unavailable
- Heparin resistance (antithrombin III deficiency) in patients requiring heparin
The older 2006 ASA guidelines specify 3:
- PT >1.5× normal or INR >2.0, or aPTT >2× normal in presence of excessive microvascular bleeding
Dosing
Standard dose: 10-15 ml/kg to achieve minimum 30% plasma factor concentration 3, 2
Warfarin reversal: 5-8 ml/kg usually suffices 3
Critical Caveats - When FFP is NOT Indicated
The 2025 guidelines explicitly state FFP should NOT be used for 1:
- Prophylactic correction of abnormal coagulation tests prior to low-risk invasive procedures in critically ill patients
- Routine use in cirrhosis/liver disease unless significant coagulopathy identified (abnormal PT/APTT are poor predictors of bleeding in stable critically ill patients)
- Prophylactic use in elective cardiac surgery
- Volume replacement alone
The 2025 CHEST guidelines recommend against routine prophylactic FFP for central venous catheter or arterial line insertion in coagulopathic patients 4.
Definition of Disseminated Intravascular Coagulation (DIC)
DIC is an acquired, life-threatening intravascular disorder characterized by systemic coagulation activation, dysregulated fibrinolysis, and endothelial injury, resulting in microthrombosis that progresses from a potentially asymptomatic early phase to an advanced phase with hemorrhage and/or organ dysfunction 5, 6.
Updated 2025 ISTH Definition
The International Society on Thrombosis and Haemostasis released updated definitions in 2025, fundamentally revising the 2001 framework 5, 6:
Key pathophysiological features:
- Systemic coagulation activation
- Dysregulated fibrinolysis
- Endothelial injury
- Microthrombosis formation
- Arises from various underlying etiologies
Phase-Based Classification (2025)
DIC is now understood as a dynamic, progressive condition with three phases 5, 6:
- Pre-DIC: Preclinical laboratory abnormalities
- Early-phase DIC (subclinical/compensated): Laboratory abnormalities preceding clinical symptoms
- Overt DIC: Advanced stage with clear coagulopathy and organ failure
Diagnostic Criteria
Early-Phase DIC (Sepsis-Induced Coagulopathy)
For septic patients, the Sepsis-Induced Coagulopathy (SIC) score identifies early DIC 7, 5:
- Platelet count
- PT-INR
- Sequential Organ Failure Assessment (SOFA) score
Overt DIC Scoring (2025 Updated)
The refined ISTH overt DIC scoring system includes 5, 6:
D-dimer thresholds (revised):
3× upper normal limit = 2 points
7× upper normal limit = 3 points
Additional parameters:
- Platelet count
- PT-INR
- Fibrinogen levels
Clinical Phenotypes
DIC manifests in two distinct patterns 5, 6:
- Thrombotic DIC: Microvascular thrombosis and organ dysfunction predominate
- Hemorrhagic DIC: Bleeding due to consumption of coagulation factors
Clinical Context
The 2019 ISTH consensus emphasizes that DIC represents a thromboinflammatory response in sepsis, where endothelial injury and circulatory abnormalities cause multi-organ failure 7. Early identification is pivotal for targeting anticoagulant therapy, as patients with advanced coagulopathy may no longer benefit from intervention.
Common pitfall: The original 2001 definition viewed DIC as an untreatable sequela requiring only treatment of the underlying cause. Current understanding recognizes that DIC-associated mortality may be reduced by detection and treatment at an early stage 5.